Potential for bacteriophage therapy for Staphylococcus aureus pneumonia with influenza A coinfection.
Future Microbiol
; 16(3): 135-142, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-1110198
ABSTRACT
The ability of influenza A virus to evolve, coupled with increasing antimicrobial resistance, could trigger an influenza pandemic with great morbidity and mortality. Much of the 1918 influenza pandemic mortality was likely due to bacterial coinfection, including Staphylococcus aureus pneumonia. S. aureus resists many antibiotics. The lack of new antibiotics suggests alternative antimicrobials, such as bacteriophages, are needed. Potential delivery routes for bacteriophage therapy (BT) include inhalation and intravenous injection. BT has recently been used successfully in compassionate access pulmonary infection cases. Phage lysins, enzymes that hydrolyze bacterial cell walls and which are bactericidal, are efficacious in animal pneumonia models. Clinical trials will be needed to determine whether BT can ameliorate disease in influenza and S. aureus coinfection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Influenza A virus
/
Pneumonia, Staphylococcal
/
Staphylococcus aureus
/
Bacteriophages
/
Influenza, Human
/
Coinfection
/
Phage Therapy
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Future Microbiol
Journal subject:
Microbiology
Year:
2021
Document Type:
Article
Affiliation country:
Fmb-2020-0163
Similar
MEDLINE
...
LILACS
LIS